Clinical Trials Sponsored by Merck+Sharp+%26+Dohme+LLC

Total 3969 results

Merck Sharp & Dohme LLC

Completed

A Study of Ascending Multiple Doses of Oral Surotomycin in Healthy Participants (MK-4261-009)

Clostridium Difficile Associated Diarrhea (CDAD)
Merck Sharp & Dohme LLC

Completed

A Clinical Study to Determine Biomarkers of Response to a Gamma Secretase Inhibitor

Healthy
Merck Sharp & Dohme LLC

Completed

An Eighteen Month Efficacy and Safety Study in Obese Patients (0364-020)(COMPLETED)

Obesity and Obesity-related Medical Conditions
Merck Sharp & Dohme LLC

Completed

Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus (T2DM)
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)

Heterozygous Familial Hypercholesterolemia (HeFH)
Merck Sharp & Dohme LLC

Approved for marketing

Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)

HIV Infections
Merck Sharp & Dohme LLC

Completed

Study of Diquafosol Tetrasodium Ophthalmic Solution in Subjects With Dry Eye Disease

Dry Eye Disease
Merck Sharp & Dohme LLC

Completed

A Study to Test Once-Weekly Doses of Odanacatib (MK0822) on Healthy Adult Females (0822-005)(COMPLETED)

Osteoporosis
Merck Sharp & Dohme LLC

Completed

A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)

Diabetes Mellitus, Non-Insulin-Dependent
Merck Sharp & Dohme LLC

Completed

Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Completed

Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058)

Non-Small Cell Lung Cancer
Merck Sharp & Dohme LLC

Completed

Single Doses of MK-0941 in Type 2 Diabetics (MK-0941-027)

Type 2 Diabetes
Merck Sharp & Dohme LLC

Terminated

Study Assessing Single and Multiple Doses of IDX21459 in Healthy and HCV-Infected Subjects

Chronic Hepatitis C
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics of IDX719 in Participants With Normal and Impaired Hepatic Function (MK-1894-008)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

A Drug-Drug Interaction Study Evaluating the Combination of IDX320 and IDX184 in Healthy Participants (MK-6844-002)

Chronic Hepatitis C
Merck Sharp & Dohme LLC

Completed

The Effect of Hypertension Medications on Renal Blood Flow Measurements in Healthy Males (MK-0000-127)

Hypertension
Merck Sharp & Dohme LLC

Completed

MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012)

Osteoporosis | Postmenopausal Osteoporosis
Merck Sharp & Dohme LLC

Terminated

Exercise Study in Patient With Chronic Obstructive Pulmonary Disease (0000-036)

Chronic Obstructive Pulmonary Disease (COPD)
Merck Sharp & Dohme LLC

Completed

Evaluate the Safety and Efficacy of Caspofungin Acetate as Empirical Therapy in Chinese Adults With Persistent Fever and Neutropenia (0991-055)

Fungal Infection
Merck Sharp & Dohme LLC

Terminated

A Study to Test a Measure of Symptoms of Older Men With Low Testosterone On and Off Testosterone Replacement Treatment (P05815)

Hypogonadism
Merck Sharp & Dohme LLC

Completed

A Study of MK0777 in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-020)

Anxiety Disorders
Merck Sharp & Dohme LLC

Terminated

A Double-masked, Randomized, Placebo-controlled,Pilot Study of Diquafosol Tetrasodium in Subjects Following Photorefractive Keratectomy (PRK)

Photorefractive Keratectomy
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED)

Measles | Rubella | Mumps | Varicella
Merck Sharp & Dohme LLC

Terminated

Study 08-114 Open-label Extension of Study 08-110 - A Multi-Center Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis Lung Disease (P08642) (DEFY)

Cystic Fibrosis
Merck Sharp & Dohme LLC

Terminated

Adherence in Patients Receiving PegIntron and Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04206)

Hepatitis C, Chronic | Hepacivirus
Merck Sharp & Dohme LLC

Completed

Assessment of Long-Term Infliximab for Psoriasis (P05319) (REALITY)

Psoriasis
Merck Sharp & Dohme LLC

Terminated

A Study of MK2578 in Patients With Chronic Kidney Disease Who Are Not on Dialysis (2578-002)

Anemia | Chronic Kidney Disease
Merck Sharp & Dohme LLC

Completed

Treatment of Cognitive Impairment in Men With Schizophrenia (MK5757-005)(COMPLETED)

Schizophrenia
Merck Sharp & Dohme LLC

Completed

Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis (CF) Lung Disease

Cystic Fibrosis

United States, Australia, Canada, New Zealand
Merck Sharp & Dohme LLC

Terminated

A Study of the Efficacy and Safety of MK2578 for the Treatment of Anemia in Patients With Kidney Disease (MK2578-003-AM03-EXT12)

Anemia | Chronic Kidney Disease
Merck Sharp & Dohme LLC

Completed

Comparison of 2.0 mg/kg Sugammadex and Neostigmine at Reappearance of T2 in Chinese and European Subjects (Study 19.4.324)(P05768AM1)(COMPLETED)

Anesthesia, General | Neuromuscular Blockade
Merck Sharp & Dohme LLC

Terminated

Safety and Efficacy Study of IL-10 (Tenovil TM) in the Prevention of Post-ERCP Acute Pancreatitis (Study P02580)(TERMINATED)

Gallbladder Diseases | Biliary Tract Diseases | Pancreatic Diseases | Pancreatitis | Bile Duct Diseases
Merck Sharp & Dohme LLC

Completed

GEM 1.5 mg b.i.d. to 4.5 mg b.i.d. Versus Lorazepam in GAD (0777-026)

Anxiety Disorder
Merck Sharp & Dohme LLC

Completed

A Dose-Finding Study of MK0974 in Acute Migraine (MK0974-004)

Migraine
Merck Sharp & Dohme LLC

Completed

Treatment of Patients With Anxiety Disorder (0777-022)

Generalized Anxiety Disorder
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)

Primary Hypercholesterolemia | Mixed Hyperlipidemia
Merck Sharp & Dohme LLC

Completed

EEG (Electroencephalogram) Platform Standardization in Healthy Male Subjects (3134-010)

Dementia
Merck Sharp & Dohme LLC

Completed

Study of the Effect of SCH 900538 on Congestion in Subjects With Seasonal Allergic Rhinitis (Study P05031)(COMPLETED)

Seasonal Allergic Rhinitis
Merck Sharp & Dohme LLC

Completed

Protocol for Eslax Intravenous Drug Use Investigation (Study P06082)

Anesthesia
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Tolerability of V419 in Healthy Infants at 2,4, 6 and 12 to 14 Months of Age (V419-003)

Bacterial Infections; Virus Diseases
Merck Sharp & Dohme LLC

Completed

A Study to Test the Safety and Effectiveness of an Investigational Vaccine in Infants (V419-002)

Bacterial Infections; Virus Diseases
Merck Sharp & Dohme LLC

Completed

A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)

Measles | Rubella | Mumps | Varicella
Merck Sharp & Dohme LLC

Completed

Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005)

HPV 16 Infection
Merck Sharp & Dohme LLC

No longer available

Post Marketing Surveillance Study of Cuprimine

Scleroderma
Merck Sharp & Dohme LLC

Completed

A Study to Test the Safety and Efficacy of MK-8998 in Acutely Psychotic Participants With Schizophrenia (MK-8998-004)

Schizophrenia
Merck Sharp & Dohme LLC

Completed

Efficacy of PegIntron (Peginterferon Alfa-2b) and Rebetol (Ribavirin) in Treatment-naïve Subjects With Chronic Hepatitis C in Clinical Practice in Greece (Study P05209)

Hepatitis C | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

A Pharmacokinetic Evaluation Study in Healthy Volunteers

Healthy
Merck Sharp & Dohme LLC

Completed

Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED)

Chronic Hepatitis C
Merck Sharp & Dohme LLC

Withdrawn

Study of SCH 527123 in Subjects With Severe Asthma (Study P05109AM1)

Asthma
Merck Sharp & Dohme LLC

Completed

Effects of Niaspan™ on High-density Lipoprotein (HDL) in Healthy Male Subjects (0000-069)

Dyslipidemia

3

Subscribe